Tumour progression is regulated by a number of stimulators and inhibitors of tumour angiogenesis (Folkman, 1995) . Among the angiogenesis stimulators, vascular endothelial growth factor (VEGF) has been shown to be the most powerful mitogen for endothelial cells. Among VEGF members, VEGF-C has recently been found to induce not only angiogenesis but also lymphangiogenesis via VEGF receptor-2 (VEGFR-2) and VEGF receptor-3 (VEGFR-3) (Mustonen et al, 1995; Cao et al, 1998; Yonekura et al, 1999) . A few researchers have reported the possible association of VEGF-C expression with intratumoural lymphatic vessel density or lymph node metastasis in some neoplasms (Ohta et al, 1999; Tsurusaki et al, 1999; Yonemura et al, 1999; Akagi et al, 2000; Niki et al, 2000) . Of importance, some studies have recently shown that VEGF-C-mediated tumour lymphangiogenesis promotes cancer metastasis including nodal metastasis (Mandriota et al, 2001; Skobe et al, 2001 ). In the present study, we assessed the expression of VEGF-C and its receptors to better delineate their association with lymph node metastasis and cancer progression in non-small cell lung cancer.
MATERIALS AND METHODS

Tissue samples
Tumour samples were randomly obtained from 62 patients who had received surgery in the Kanazawa University Hospital between 1996 and 1997. For the immunohistochemical study, consecutive 6 µm-thick sections were cut from the tumour margin. The pathologic classification of each sample was confirmed by a review of haematoxylin and eosin (H&E)-stained sections. The pathological types were 36 adenocarcinomas, 20 squamous cell carcinomas, 2 adenosquamous carcinomas and 4 large cell carcinomas. The pathological stages were classified as stage I in 28 patients, II in 7, III in 26 and IV in 1 according to the Japanese Lung Cancer Society Classification.
Immunohistochemistry for VEGF-C and VEGFRs
The primary antibodies used in this study were an anti-VEGF-C goat polyclonal antibody at 1:200 dilution (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA), an anti-VEGFR-3 rabbit polyclonal antibody at 1:200 dilution (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA), an anti-VEGFR-2 rabbit monoclonal antibody at 1:200 dilution (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA) and an anti-CD34 mouse monoclonal antibody (Nichirei, Tokyo, Japan). Paraffin sections were deparaffinized and immunohistochemical staining was performed using the immunoperoxidase technique. Endogenous peroxidase was blocked by treatment with 0.3% hydrogen peroxide in methanol for 15 min, and the sections were washed with Dulbecco's phosphate-buffered saline (pH 7.2) without calcium ion or magnesium ion (PBS-). Tissue non-specific binding sites were blocked by 10% normal rabbit serum for VEGF-C, and by 10% normal goat serum for VEGFR-2, VEGFR-3 and CD34 for 15 min at room temperature. After they had been washed with PBS-, the sections were reacted with antibodies for 16 h at 4°C. Then they were washed with PBS-and reacted with biotinylated second antibody for 30 min at room temperature. After they had been washed with PBS-, avidin-biotin-peroxidase complex (DAKO LSAB2 system, DAKO Co, Carpinteria, CA, USA) was added and colour was developed using 3-3′-diaminobenzidine (Sigma, St Louis, MO, USA) with 0.03% hydrogen peroxide. Counterstaining was done with haematoxylin. For the negative control, all reagents except for the primary antibody were used. The specificities of VEGF-C and VEGFR-3 were The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer tested using a blocking peptide (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA).
Assessment of microvessel density and immunohistochemical assessment of VEGF-C, VEGFR-2, and VEGFR-3
The total number of vascular endothelial cells was determined by immunohistochemistry for CD34 (Figure 1 ). The number was assessed blindly by 2 investigators. After the areas of highest vascularization had been chosen under low power (100 × magnification), vessel count within tumours was carried out in 3 fields on the screen image which was captured at 200 × magnification. The average counts of the 3 fields were recorded, and the mean value of the 2 investigators was used for the total number. For evaluation of immunostainings, cases in which at least 5% of tumour cells were immunoreactive were defined as being positive. As for the VEGFR-2 and VEGFR-3 staining within tumour cells, cases in which more than 50% of tumour cells were immunoreactive were defined as being strongly positive. As for the VEGFR-2 and VEGFR-3 staining within endothelial cells, after counting the total number of endothelial cells by CD34 staining as described above, the number of VEGFR-2-or VEGFR-3-positive endothelial cells was determined in the same manner by using consecutive paraffin sections. Cases in which at least 5% of endothelial cells were immunoreactive were defined as being positive in this study.
Western blot analysis of VEGFR-3 in human lung cancer cell lines
5 human lung cancer cell lines (PC-3, PC-8, PC-10, PC-14, QG-56) were used and maintained in RPMI-1640 media (Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 10 mM HEPES buffer, 500 units ml -1 pencillin and 500 units ml -1 streptomycin at 37°C and 5% CO 2 . HUVEC was used as a positive control for VEGFR-3 and maintained in medium 199 (Life Technologies, Grand Island, NY, USA) supplemented with 20% FBS, 100 µg ml -1 EC growth supplement, 50 U ml -1 heparin, glutamine and antibiotics. 20 µg of protein sample were obtained from each cell line and mixed with 6 µl of sample buffer (50 mM Tris-HCL (pH 6.5), 10% glycerol, 2% SDS, and 0.1% bromphenol blue) prior to separation by 10% sodium dodecyl sulfate-polyacrylamide gel, followed by electrophotetic transfer of the proteins to a PVDF membrane (Millipore, Bedford, MA). The transferred samples were reacted with an anti-VEGFR-3 polyclonal antibody at 1:1000 dilution (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA) and anti-β-actin monoclonal antibody (Sigma Chemical Co, St Louis, MO) for 2 h at room temperature. Secondary antibody, anti-mouse coupled to horseradish peroxidase, was incubated with the membrane and then washed in TBS-T. The presence of secondary antibody bound to membrane was detected by using the ECL Western blotting detection reagent (Amersham Life Science, Buckinghamshire, UK). As a negative control, primary VEGFR-3 antibody, which was pre-absorbed with the blocking peptide (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA) overnight was used.
Statistics
Fisher's exact test was used to examine the association between different variables and clinicopathological factors. Survival curves were obtained using the Kaplan-Meier method and compared using the log-rank test. A multivariate model using the Cox stepwise regression analysis was used to evaluate the statistical strength of independent association between selected covariates and patient survival. A P value less than 0.05 was considered significant.
RESULTS
VEGF-C, VEGFR-2 and VEGFR-3 expression in lung cancer tissue
VEGF-C antigen was observed in the cytoplasm of cancer cells (Figure 2) . No staining was observed in the normal lung tissue. VEGF-C expression was positive in 38.7% (24/62) of the lung cancer patients. VEGFR-2 and VEGFR-3 antigens were observed in the cytoplasm of endothelial cells and cancer cells (Figure 3) . The percentages of patients with positive VEGFRs in endothelial cells were 64.5% (40/62) for VEGFR-3 and 74.1% (46/62) for VEGFR-2. The percentages of patients with positive VEGFRs in cancer cells were 77.4% (48/62) for VEGFR-3 and 100% (62/62) for VEGFR-2. The percentages of the patients with strongly positive VEGFR staining in cancer cells were 27.4% (17/62) for VEGFR-3 and 51.6% (32/62) for VEGFR-2. A significant positive correlation was found between VEGF-C expression in cancer cells and VEGFR-3 expression in endothelial cells (P < 0.01), but not between VEGF-C in cancer cells and VEGFR-2 in endothelial cells (Table 1) . Moreover, the expression of VEGF-C in cancer cells was also significantly associated with the intensities of both VEGFR-2 and VEGFR-3 staining in cancer cells (both P < 0.05) (Tables 1, 2). As a result of the Western blot analysis, a M r 125 000 band corresponding to VEGFR-3 protein was detected in all 5 lung cancer cell lines used (Figure 4) . Table 3 shows the correlations between clinicopathological factors and VEGF-C expression. VEGF-C expression was more frequently found in tumours with lymph node metastasis than in those without it (P < 0.05). VEGF-C expression in tumours with lymphatic invasion was significantly greater than that in tumours 
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without lymphatic invasion (P < 0.05). The VEGF-C expression was also significantly associated with gender and pathological stage (both P < 0.05) ( Table 3) . Figure 5 shows the survival of patients according to the VEGF-C status. Patients with VEGF-C expression had significantly poorer outcomes compared to those without (P < 0.05). From multivariate analysis, VEGFR-2 expression in endothelial cells, T factor and N factor retained independent negative prognostic impact on overall survival (Table 4) .
Correlations of clinicopathological and biological factors with survival
DISCUSSION
The findings of the current study demonstrated the positive association of VEGF-C expression with both lymph node metastasis and lymphatic invasion in lung cancer. In addition, a significant positive correlation was clearly found between VEGF-C expression in cancer cells and VEGFR-3 expression in endothelial cells. A positive association of VEGF-C expression with lymph node metastasis has been reported in gastric cancer, prostatic cancer, lung adenocarcinoma, and colorectal cancer (Tsurusaki et al, 1999; Yonemura et al, 1999; Akagi et al, 2000; Niki et al, 2000) . A significant correlation between VEGF-C and VEGFR-3 has also been found in malignant mesothelioma and gastric cancer (Ohta et al, 1999; Yonemura et al, 1999) . Our results indicated the possibility that VEGF-C produced in lung cancer cells modulates lymphatic metastasis through its receptor, VEGFR-3, in endothelial cells.
To our knowledge, this is the first report that described the prognostic aspect of VEGF-C expression in lung cancer. The lung cancer patients with VEGF-C expression had significantly poorer outcomes compared to those without it. Although we could find no prognostic independency in VEGF-C and VEGFR-3, the VEGFR-2 expression in endothelial cells retained significance. Since VEGFR-2, which is a receptor for VEGF, VEGF-C, VEGF-D and VEGF-E, is known to also act as the main regulator of endothelial cell proliferation and migration (Waltenberger et al, 1994; Joukov et al, 1996; Ferrara and Davis-Smyth 1997; Achen et al, 1998; Meyer et al, 1999) , we speculate that VEGFR-2 plays a key role in tumour angiogenesis and tumour progression/development in lung cancer. It is notable that our immunohistochemical study showed positive VEGFR stainings not only in endothelial cells but also in cancer cells. Both VEGFR-1 and VEGFR-2 expressions have been observed in breast cancer, ovarian cancer, prostatic cancer and melanoma in addition to lung cancer (Gitay-Goren et al, 1993; Boocock et al, 1995; Lu and Brodie, 1996; Decaussin et al, 1999; Ferrer et al, 1999; Speirs and Atkin 1999; Xie et al, 1999) . On the other hand, although the existence of VEGFR-3 expression in cancer cells has been reported in malignant mesothelioma, Kaposi's sarcoma, vascular tumour and melanoma (Pajusola et al, 1992; Jussila et al, 1998; Lymboussaki et al, 1998; Ohta et al, 1999) , there has been no report on VEGFR-3 expression within lung cancer cells. Our results demonstrated here seem to strengthen the notion that lung cancer cells express VEGFR-3. Considering the positive association found between VEGF-C expression in lung cancer cells and VEGFR-2/VEGFR-3 stainings in cancer cells, the role of VEGF-C may encompass the tumour growth regulation in both paracrine and autocrine fashion. Although the prognostic impact of VEGFRs expression within cancer cells was not clear in this study, examination of the activation status through tyrosin phosphokinase is required to further elucidate the roles of VEGFRs in lung cancer cells.
In conclusion, this study enlightens the evidence that VEGF-C expression within cancer cells and VEGFR-3 expression within endothelial cells are of influence on the lymphatic metastasis in non-small cell lung cancer. Further analysis concerning lymphangiogeneis within tumour should be a promising way to understand the mechanism underlying the lymphatic metastasis in non-small cell lung cancer. 
